Whitney Hensing, MD
Hematology & Oncology · Kansas City, MONPI 1760832711
Payments from drug & device makers
What this record shows
This record is dominated by grants: $50,000 of the $62,124 with a category attached, or 80.5%. Genentech, Inc. accounts for 80.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $50,134 and has fallen 93.5% since, to $3,256 in 2025. Among hematology & oncology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 31 payments — averaging $2004.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$50K
- Gilead$4K
- AstraZeneca$4K
- Novartis$3K
- Takeda Pharmaceuticals U.S.A., Inc.$100
- Astellas Pharma US Inc$100
- plus $34 from 1 others
Across 5 payments — averaging $70,028 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$308K
- AstraZeneca$33K
- Pfizer$10K
What the payments were for
- Consulting fees$11,03618%
- Grants$50,00080%
- Food & beverage$8881%
- Education$2000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 2 | $50,000 |
| Gilead | 8 | $4,446 |
| AstraZeneca | 11 | $4,121 |
| Novartis | 6 | $3,324 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $100 |
| Astellas Pharma US Inc | 1 | $100 |
| Johnson & Johnson | 2 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,124 in reported general payments places this provider in the 95th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 34 | $546,868 |
| EliquisApixaban | 29 | $20,226 |
| Anastrozole | 296 | $4,666 |
| Letrozole | 108 | $3,694 |
| Exemestane | 14 | $1,817 |
| Tamoxifen Citrate | 67 | $1,557 |
| Fentanyl | 15 | $906 |
| Oxycodone Hcl | 18 | $519 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $516 |
| Ondansetron Hcl | 29 | $468 |
| YuvafemEstradiol | 14 | $387 |
| Duloxetine Hcl | 24 | $379 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $367 |
| Omeprazole | 14 | $321 |
| Gabapentin | 28 | $316 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Kansas City
- Shahzad RazaKansas City$123K
- Stephanie GraffKansas City$105K
- Jaswinder SinghKansas City$46K
- Suman KambhampatiKansas City$31K
- Nicholas ShulerKansas City$18K
- Marc RothKansas City$12K
- Tolga TuncerKansas City$10K
- Karan JosanKansas City$8K
- Maureen SheehanKansas City$8K
- David SchlossmanColumbia$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.